Targeting Ribosome Biogenesis to Combat Tamoxifen Resistance in ER+ve Breast Cancer

• Published in: Cancers Vol. 14; no. 5; p. 1251
• Main Authors: Tsoi, Ho, You, Chan-Ping, Leung, Man-Hong, Man, Ellen P. S., Khoo, Ui-Soon
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 28.02.2022; MDPI
• Subjects: Apoptosis; Biosynthesis; Breast cancer; c-Myc protein; Cancer therapies; Cell cycle; Cell division; Cell growth; Cell proliferation; Cyclin-dependent kinases; Endocrine therapy; Estrogen receptors; Estrogens; Gene expression; Genomes; Initiation factor eIF-4E; Kinases; Ligands; Localization; Metabolism; Metastases; Metastasis; MicroRNAs; Myc protein; Proteins; Review; Ribosomes; Tamoxifen; Transcription factors; Transcriptomes; Tumors; breast cancer; eIF4E; tamoxifen resistance; c-MYC; ribosome biogenesis

Breast cancer is a heterogeneous disease. Around 70% of breast cancers are estrogen receptor-positive (ER+ve), with tamoxifen being most commonly used as an adjuvant treatment to prevent recurrence and metastasis. However, half of the patients will eventually develop tamoxifen resistance. The overex...